To dissolve existing crystals and halt
new crystals from forming, treatment
guidelines recommend keeping sUA levels
consistently at or below 360 μmol/L
(6 mg/dL) in patients with gout,
which is below the MSU saturation point.
1-5
References: 1. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the
EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312-1324. 2. Richette P, Doherty M,
Pascual E, et al. Updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2014;73(suppl 2):S783-S784. 3. Khanna D,
Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and
pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431-1446. 4. Sivera F, Andres M, Carmona L, et al.
Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a
broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014;73(2):328-335. 5. Jordan KM, Cameron JS, Snaith M, et al. British Society for
Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007;46(8):1372-1374.